SCHEMBL21591484

SCHEMBL21591484

O=c1c(CCl)coc2cc(Br)ccc12

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ PKM P14618 1/20 0.44
▸ MAOB P27338 4/20 0.42
▸ PTPN1 P18031 1/20 0.42
▸ CYP11B1 P15538 7/20 0.42
▸ CYP11B2 P19099 7/20 0.42
▸ CYP19A1 P11511 4/20 0.42
▸ CYP17A1 P05093 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ HSP90AA1 P07900 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ SIGMAR1 Q99720 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17378987 0.86 MAPT (0.38) MAPTALDH1A1PKMMAOBPTPN1
SCHEMBL21591553 0.81 CYP11B1 (0.62) ALDH1A1MAOBPTPN1CYP11B1CYP11B2
SCHEMBL21591546 0.77 CYP11B1 (0.64) MAPTALDH1A1MAOBCYP11B1CYP11B2
SCHEMBL29591394 0.76 PTPN1 (0.46) MAPTALDH1A1MAOBPTPN1GAA
SCHEMBL9075843 0.76 MAOB (0.71) ALDH1A1MAOBPTPN1CYP11B1CYP11B2
SCHEMBL21954375 0.76 PTPN1 (0.46) MAPTALDH1A1MAOBPTPN1GAA
SCHEMBL21591476 0.75 CYP11B1 (0.37) ALDH1A1MAOBPTPN1CYP11B1CYP11B2
SCHEMBL28477936 0.75 ALDH1A1 (0.47) MAPTALDH1A1PKMMAOBPTPN1
SCHEMBL28990341 0.75 ALDH1A1 (0.47) MAPTALDH1A1PKMMAOBPTPN1
SCHEMBL1530595 0.74 MAPT (0.39) MAPTALDH1A1PKMMAOBPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12162863-B2 Modulators of stimulator of interferon genes (STING) Ryvu Therapeutics S.A. (PL) 2024-12-10 — — US disclosed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 — — US disclosed
EP-3807264-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2021-04-21 — — EP disclosed
WO-2019238786-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2019-12-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162863-B2 Modulators of stimulator of interferon genes (STING) STING1, IRF3, CGAS MAPT 1787/4885ALDH1A1 4462/4885PKM 3137/4885
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) STING1, IRF3, CGAS MAPT 1787/4885ALDH1A1 4462/4885PKM 3137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback